BiondVax Pharmaceuticals Ltd. announced that Angels High Tech Investments Ltd. has agreed to invest NIS 10.9 million, approximately $US 2.83 million, in exchange for 33.8 million ordinary BiondVax shares on the Tel Aviv Stock Exchange (equivalent to 844,000 NASDAQ listed ADS) at the December 29, 2016 Tel Aviv closing market price. Following the transaction, Angels Investments will hold 19.99% of all issued and outstanding share capital of the Company.
Angels Investments is a company fully owned by Marius Nacht, Co-founder and chairman of Check Point. Angels’ healthcare and life science portfolio is managed by aMoon Partners which is co-led by Dr. Yair Schindel and Marius Nacht.
Ron Babecoff, BiondVax’s founder, president and CEO noted, “This investment is a vote of confidence in BiondVax and its universal influenza vaccine candidate. We are now better positioned to complete our development plans and commercialize our vaccine worldwide. This strategic partnership, together with clinical results and ongoing clinical trial collaborations in Europe and the US (NIH) will enable us to proceed confidently into Phase 3 as planned.”
Dr. Yair Schindel, aMoon Partners’ Co-founder and Managing Partner commented, “We see great potential in BiondVax’s universal flu vaccine. We expect that this investment is the beginning of a strong partnership with BiondVax and we look forward to doing our part in helping reduce the global morbidity and mortality caused by influenza viruses.”
BiondVax is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains.
Biondvax to receive, investment, angels high tech investments
9.jpg)
